GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Weed Inc (OTCPK:BUDZ) » Definitions » Capex-to-Revenue

Weed (BUDZ) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Weed Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Weed's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Weed Capex-to-Revenue Historical Data

The historical data trend for Weed's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Weed Capex-to-Revenue Chart

Weed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Weed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Weed's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Weed's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Weed's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Weed's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Weed's Capex-to-Revenue falls into.



Weed Capex-to-Revenue Calculation

Weed's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.01) / 0
=N/A

Weed's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Weed  (OTCPK:BUDZ) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Weed Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Weed's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Weed (BUDZ) Business Description

Traded in Other Exchanges
N/A
Address
4920 North Post Trail, Tucson, AZ, USA, 85750
Weed Inc is working on or planning for several different business opportunities in the cannabis and hemp field, including, but not limited to both indoor and outdoor grows, cultivations, and harvest for research, product development, processing, and manufacturing of both Pharma and non-Pharma products, services, therapeutics, and treatments on a global basis for both the Medical Cannabis and Hemp global market space.
Executives
Nicole M Breen director, 10 percent owner, officer: Secretary/Treasurer 4920 N. POST TRAIL, TUCSON AZ 85750
Elliot Kwestel director 5 AUERBACH LANE, LAWRENCE NY 11559
Lawrence G Dykers director 11924 N CENTAURUS PLACE, ORO VALLEY AZ 85737
Glynn A Burkhardt director, 10 percent owner, officer: Senior Vice President 3400 E. SPEEDWAY BLVD., SUITE 118-300, TUCSON AZ 85716
Roger Mccaslin director 11924 N. CENTAURUS PLACE, ORO VALLEY AZ 85737
Glenn E. Martin director, 10 percent owner, officer: President and Chairman of BOD 4920 N. POST TRAIL, TUCSON AZ 85750
Robert A Metz director, officer: Vice President 3400 E. SPEEDWAY BLVD., SUITE 118-300, TUCSON AZ 85716
Robert A Leitzman director, officer: CFO, CAO and V.P. 3400 E. SPEEDWAY BLVD., SUITE 118-300, TUCSON AZ 85716
Glynn A. Burkhardt director, 10 percent owner, officer: Senior V.P. 11924 N. CENTAURUS PLACE, ORO VALLEY AZ 85737
Donald J Steinberg director, officer: Former Officer and Director 3223 SUMAC ROAD, FALLBROOK CA 92028

Weed (BUDZ) Headlines

From GuruFocus

WEED Inc. 'SALUTES' our Veterans & Arizona's Historic VOTE

By ACCESSWIRE ACCESSWIRE 11-11-2020